We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Different Test Systems Analytical Performance Evaluated for Serum Creatinine

By LabMedica International staff writers
Posted on 13 Jan 2022
Print article
Image: The cobas CREP2 reagent kit: an in vitro test for the quantitative determination of creatinine in serum, human plasma and urine (Photo courtesy of Roche Diagnostics)
Image: The cobas CREP2 reagent kit: an in vitro test for the quantitative determination of creatinine in serum, human plasma and urine (Photo courtesy of Roche Diagnostics)
Creatinine is a breakdown product of creatine phosphate from muscle and protein metabolism. It is produced and released by the body at a constant rate into the blood, and it is then carried to the kidneys through the blood circulation.

In clinical practice, the level of serum creatinine (SCr) is generally used as a significant indicator for renal function evaluation. SCr determination is a widely applied diagnostic test to evaluate glomerular filtration rate (GFR) that when renal function is impaired, the creatinine level rises. Clinical methods for serum creatinine determination include chemical and enzymatic methods.

Clinical Laboratorians at the University of Chinese Medicine (Guangzhou, China) obtained serum samples by collecting surplus samples from routine creatinine tests. Specimens for method comparison study were collected from left-over clinical 34 patient samples, with creatinine levels ranging from 45 to 1,610 μmol/L. Precision, accuracy, linearity, dilution, lower limit of measurement and analytical interference were studied between two test systems.

The scientists used the open test system, namely the Shino-Test creatinine reagent kit (Shino-Test Corp., Tokyo, Japan), and the Roche Cobas 8000 c702 chemistry analyzer (Roche Diagnostics, Mannheim, Germany) to determine creatinine levels. The determination results were analyzed and compared with those obtained from the matched test system, Roche creatinine reagent kit and the same analyzer. An interference study was carried out by adding different solutions of interferents to serum pools at three levels of creatinine. To study the influence of hemolysis, hemolysate was added to each serum pool aliquot. Interference studies of vitamin C or dobutamine were carried out by mixing serum pool aliquots with serial dilutions of vitamin C solution or dobutamine injection.

The investigators reported that the performance of SCr from the open test system was in compliance with the matched test system with good precision, accuracy, and linearity. In presence of most common interferents, both test systems could lead to accurate creatinine results except for the existence of specified drugs. For dobutamine, the open test system showed better anti-interference performance than the matched system. The results showed that either matched test system or open test system presented extremely low imprecision at each level evaluated.

The authors concluded that their study provided referable opinions for clinical laboratory selection on the test system and a framework for future analogous studies based on different test systems. Clinicians and laboratory professionals should be mindful of potential interference caused by specified medications such as calcium dobesilate and dobutamine because an inaccurate creatinine result may lead to serious untoward consequences. The study was published on December 26, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Chinese Medicine
Shino-Test Corp
Roche Diagnostics

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
5-Part Automatic Hematology Analyzer
Silver Supplier
Modular Sequencing Workstation
Gold Supplier
POC Test Reader

Print article


Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

System Separates Circulating Tumor Cells from Blood Samples, Improves Cancer Diagnostics

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.